by Peter Ciszewski | Dec 22, 2020
Miles Prince, MD, from Peter MacCallum Cancer Centre, discusses 5-year follow-up data from the ECHELON-2 study presented at ASH 2020. The ECHELON-2 study was a double-blind, randomized, multicenter, phase 3 clinical trial that finished in 2018. It compared the...
by Peter Ciszewski | Dec 22, 2020
Roberto Salvatori, MD, Medical Director, Johns Hopkins Pituitary Center and Professor of Medicine at Johns Hopkins discusses treatment options for acromegaly including surgical removal of the adenoma, radiotherapy, or pharmacological reduction of growth hormone (GH)...
by Peter Ciszewski | Dec 21, 2020
Thanos Zomas, MD, from Takeda Oncology, discusses follow-up data from the ECHELON-1 study presented at ASH 2020. The ECHELON-1 study was an open-label, randomized, phase 3 study of brentuximab vedotin as a frontline treatment for late-stage Hodgkin lymphoma....
by Peter Ciszewski | Dec 21, 2020
Lori Leslie, MD, Assistant Professor at Hackensack Meridian School of Medicine, discusses a study presented at ASH 2020 looking at the clinical outcomes of high-risk chronic lymphocytic leukemia (CLL) patients receiving ibrutinib. CLL is a rare blood cancer...
by Peter Ciszewski | Dec 18, 2020
Thihan Padukkavidana, MD, from Takeda Oncology, discusses data on the efficacy and safety of ponatinib in chronic-phase chronic myeloid leukemia (CML) patients. This data was presented at ASH 2020. CML is a rare blood cancer characterized by the unregulated...
